[
  {
    "EXHIBIT A": {
      "name": "ESCROW SERVICES DESCRIPTION",
      "description": "Successful completion of a transaction involves exchange of merchandise with payment. The buyer has to be satisfied he/she received what they thought they were getting and the seller has to be sure he/she gets paid. i-Escrow holds payment from the buyer in trust until the seller sends the merchandise to the buyer. Once the buyer accepts the merchandise, i-Escrow forwards the payment to the seller by writing a check. A typical escrow transaction:\n\nWhen an auction ends, your end of auction email contains links to i-Escrow.\nOnce you have signed up with i-Escrow   you go through the following steps to complete your transaction.\n1.  Start a transaction by entering the description and price of the merchandise along with email address of the other party.\n2.  The other party receives an email from i-Escrow requesting an acknowledgement of the terms of the transaction.\n3.  Once the transaction is acknowledged by the other party, the buyer pays i-Escrow the agreed upon price, by credit card or other means.\n4.  i-Escrow informs the seller that payment has been received, requesting them to ship the merchandise directly to the buyer.\n5.  The seller provides i-Escrow with the tracking number of the shipment.\n6.  The buyer receives and accepts the merchandise.\n7.  i-Escrow sends the check to the seller.\n\nFor more information about I-Escrow, visit their web-site at www.iescrow.com"
    },
    "file_id": "2ThemartComInc_19990826_10-12G_EX-10.10_6700288_EX-10.10_Co-Branding Agreement_ Agency Agreement"
  },
  {
    "EXHIBIT A": {
      "Services": [
        "Provision of software development services",
        "Website design and maintenance",
        "Content creation",
        "Digital marketing support",
        "Social media management",
        "SEO optimization",
        "Analytics tracking",
        "Data analysis",
        "Reporting and insights",
        "Training"
      ]
    },
    "Return": "Training",
    "file_id": "ABILITYINC_06_15_2020-EX-4.25-SERVICES AGREEMENT"
  },
  {
    "summary": "This contract outlines the formation of a joint venture between Collectible Concepts Group and Pivotal Self Service Tech, Inc. It details the business scope, capital contributions, division of profits, term of the agreement, and various operational responsibilities for the joint venture. It also includes provisions for termination, distribution of profits, and legal considerations.",
    "contract_type": "Joint Venture Agreement",
    "parties": [
      {
        "name": "Collectible Concepts Group, Inc.",
        "location": "1600 Lower State Road, Doylestown, PA 18901"
      },
      {
        "name": "Pivotal Self Service Tech, Inc.",
        "location": "1600 Lower State Road, Doylestown, PA 18901"
      }
    ],
    "effective_date": "2003-03-01",
    "contract_scope": "The Joint Venture is formed for the purpose of engaging generally in the business of marketing batteries and related products, including the display of licensed logos, images, and brand names.",
    "duration": null,
    "end_date": null,
    "total_amount": null,
    "governing_law": "Pennsylvania",
    "clauses": [
      {
        "summary": "Renewal & Termination",
        "clause_type": "Renewal & Termination"
      },
      {
        "summary": "Confidentiality & Non-Disclosure",
        "clause_type": "Confidentiality & Non-Disclosure"
      },
      {
        "summary": "Non-Compete & Exclusivity",
        "clause_type": "Non-Compete & Exclusivity"
      },
      {
        "summary": "Liability & Indemnification",
        "clause_type": "Liability & Indemnification"
      },
      {
        "summary": "Service-Level Agreements",
        "clause_type": "Service-Level Agreements"
      },
      {
        "summary": "Distribution of Income and Losses",
        "clause_type": "Distribution of Income and Losses"
      },
      {
        "summary": "Accounting Provisions",
        "clause_type": "Accounting Provisions"
      },
      {
        "summary": "Procedure on Termination and Liquidation",
        "clause_type": "Procedure on Termination and Liquidation"
      },
      {
        "summary": "Sale or Purchase of Interest of Joint Venturer Prohibited",
        "clause_type": "Sale or Purchase of Interest of Joint Venturer Prohibited"
      },
      {
        "summary": "Internal Revenue Code Election",
        "clause_type": "Internal Revenue Code Election"
      },
      {
        "summary": "Not Creating Partnership",
        "clause_type": "Not Creating Partnership"
      },
      {
        "summary": "No Limitation on Powers",
        "clause_type": "No Limitation on Powers"
      },
      {
        "summary": "Cooperation",
        "clause_type": "Cooperation"
      }
    ],
    "file_id": "ACCELERATEDTECHNOLOGIESHOLDINGCORP_04_24_2003-EX-10.13-JOINT VENTURE AGREEMENT"
  },
  {
    "title": "Packaging Requirements",
    "sections": [
      {
        "chapter": 5,
        "title": "Design of packaging",
        "content": "Packaging shall be designed in a suitable way to protect the packed good against transportation load according to IEC 60721-3-2 class's 2M2/2K4\nInternational pictograms following the IEC 60601 series shall be used for parts which fall under specific restrictions for transport or storage."
      },
      {
        "chapter": 3,
        "title": "Data Identifier for Expiration Date and Batch",
        "content": "The data identifier shall be used to indicate the validity of the product or the batch number."
      },
      {
        "chapter": 4,
        "title": "Labeling",
        "content": "Labeling requirements have to be defined for the product concerned. However, minimum requirements are specified in order to allow proper identification throughout all processes involved. The label depends on whether a part/component/system is serialized or not. If it is serialized, it must have the Serial Number."
      },
      {
        "chapter": 5,
        "title": "Basic requirements for packaging",
        "content": "Especially for spare parts appropriate packaging are required for the global shipping process. Should those packaging contain wood, generally 'non wood-packaging' according IPPC (International Plant Protection Convention) shall be used, but fumigation of such packaging is not allowed.  Packaging shall be designed in a suitable way to protect the packed good against transportation load according to IEC 60721-3-2 class's 2M2/2K4  International pictograms following the IEC 60601 series shall be used for parts which fall under specific restrictions for transport or storage."
      },
      {
        "chapter": 7,
        "title": "Transition and retrospective measures",
        "content": "n.a."
      },
      {
        "chapter": 8,
        "title": "Changes to prior version",
        "content": "CR-No.: 2007-005  Changes to previous edition 04798372 AND 02S 03:    \u00b7 Chapter 2: Reference document IEC 60721-3-2 added  \u00b7 Chapter 5: Design of packaging changed     CR-No. 2006-008 (CR N06/0207)  Changes to previous edition 04798372 AND 02S 02:     \u00b7 Title: Added: and basic requirements for packaging  \u00b7 Chapter 4.2 Added: Expiration date and batch  \u00b7 Chapter 4.3: Completely new    CR-No. 2006-01, 2006-02  Changes to previous edition 04798372 AND 02S 01:     \u00b7 Chapter 2, 4.2 : EN 800 replaced by ISO/IEC 16388  \u00b7 Chapter 4.2 : general requirements at the beginning stated more clearly, footnote added"
      }
    ],
    "file_id": "ACCURAYINC_09_01_2010-EX-10.31-DISTRIBUTOR AGREEMENT"
  },
  {
    "return_date": "January 13, 2005",
    "file_id": "ADAMSGOLFINC_03_21_2005-EX-10.17-ENDORSEMENT AGREEMENT"
  },
  {
    "error": "Failed to parse JSON: Expecting ',' delimiter: line 7 column 3104 (char 3318)",
    "raw": "```json\n{\n  \"documents\": [\n    {\n      \"id\": \"1\",\n      \"type\": \"document\",\n      \"name\": \"MD Anderson Cancer Center and Adaptimmune Strategic Alliance to Advance Development of Immunotherapies Targeting Multiple Cancers\",\n      \"content\": \"Adaptimmune Therapeutics plc (Nasdaq: ADAP) and The University of Texas MD Anderson Cancer Center announced that they have entered into a multi-year strategic alliance designed to expedite the development of novel adoptive T-cell therapies for multiple types of cancer.  The alliance pairs MD Anderson's preclinical and clinical teams with Adaptimmune's scientists and proprietary SPEAR\u00ae (Specific Peptide Enhanced Affinity Receptor) T-cell technology platform, which enables Adaptimmune to identify targets expressed on solid and hematologic cancers and to develop affinity enhanced T-cell receptors (TCRs) with optimal potency and specificity against them.  The teams will collaborate in a number of areas including preclinical and clinical development of Adaptimmune's SPEAR T-cell therapies targeting MAGE-A10 and future clinical stage first and second generation SPEAR T-cell therapies such as MAGE-A4 across a number of cancers. The alliance will also drive research and development of other new SPEAR TCR therapies to targets in other tumor types such as breast cancers and facilitate clinical study participation by MD Anderson in other Adaptimmune trials. Access to MD Anderson's tumor repository will guide further target selection and clinical trial design, while its cancer immunology cores and expertise in performing translational medicine studies may help optimize the efficacy and safety of SPEAR T-cell therapies.  Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, and The University of Texas MD Anderson Cancer Center announced today that they have entered into a multi-year strategic alliance designed to expedite the development of novel adoptive T-cell therapies for multiple types of cancer.  The alliance pairs MD Anderson's preclinical and clinical teams with Adaptimmune's scientists and proprietary SPEAR\u00ae T-cell technology platform, which enables Adaptimmune to identify targets expressed on solid and hematologic cancers and to develop affinity enhanced T-cell receptors (TCRs) with optimal potency and specificity against them.  The teams will collaborate in a number of areas including preclinical and clinical development of Adaptimmune's SPEAR T-cell therapies targeting MAGE-A10 and future clinical stage first and second generation SPEAR T-cell therapies such as MAGE-A4 across a number of cancers. The alliance will also drive research and development of other new SPEAR TCR therapies to targets in other tumor types such as breast cancers and facilitate clinical study participation by MD Anderson in other Adaptimmune trials.  About MD Anderson   The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution's sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 45 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No.1 for cancer care in U.S. News & World Report's \"Best Hospitals\" survey. It has ranked as one of the nation's top two hospitals since the survey began in 1990, and has ranked first for nine of the   46\n\n  E:  \"The University of Texas MD Anderson Cancer Center and Adaptimmune Strategic Alliance to Advance Development of Immunotherapies Targeting Multiple Cancers\"\n}\n```",
    "file_id": "ADAPTIMMUNETHERAPEUTICSPLC_04_06_2017-EX-10.11-STRATEGIC ALLIANCE AGREEMENT"
  },
  {
    "term_of_agreement": {
      "startDate": "2024-01-01",
      "duration": "6 months"
    },
    "termination_conditions": [
      "30 days written notice",
      "material breach",
      "insolvency",
      "assignment"
    ],
    "liability": "Not liable for compensation of loss of profit or sales.",
    "file_id": "ADIANUTRITION,INC_04_01_2005-EX-10.D2-RESELLER AGREEMENT"
  },
  {
    "error": "Failed to parse JSON: Illegal trailing comma before end of object: line 22 column 132 (char 1212)",
    "raw": "```json\n{\n  \"summary\": \"This agreement details the transfer of a batch of Rabies Fraction II Paste from ADMA BioManufacturing, LLC to Sanofi Pasteur S.A., with provisions for liability, compensation, and distribution of the product. It outlines the responsibilities of both parties, including a commitment to supply a minimum quantity of product and addressing potential losses due to non-compliance.\",\n  \"contract_type\": \"Joint Venture & Licensing\",\n  \"parties\": [\n    {\n      \"name\": \"ADMA BioManufacturing, LLC\",\n      \"location\": \"5800 Park of Commerce Boulevard NW, Boca Raton, Florida 33487 USA\"\n    },\n    {\n      \"name\": \"Sanofi Pasteur S.A.\",\n      \"location\": \"14, espace Henry Vallee, 69007, Lyon, France\"\n    }\n  ],\n  \"effective_date\": \"2017-12-21\",\n  \"contract_scope\": \"The agreement covers the transfer and management of the Rabies Fraction II Paste, detailing responsibilities for supply, liability, and compensation.\",\n  \"duration\": \"Not specified\",\n  \"end_date\": \"Not specified\",\n  \"total_amount\": \"Not specified\",\n  \"governing_law\": \"Not specified\",\n  \"clauses\": [\n    {\n      \"summary\": \"All capitalized terms used and not defined in this Amendment shall have the meaning as set out in the Agreement.\",\n    },\n    {\n      \"summary\": \"The supply terms set forth in Section 1 of Amendment #2 (the \\\"Prior Supply Terms\\\") are hereby deleted in their entirety. In their place, the Parties agree to the following (and Section 2.1 of the Agreement is hereby amended as needed to implement the following):\"\n    },\n    {\n      \"clauses\": [\n        {\n          \"summary\": \"Sanofi Pasteur agrees to supply the Product.\",\n          \"text\": \"The Product\\\" is defined as the Rabies Fraction II Paste.\"\n        },\n        {\n          \"summary\": \"ADMA agrees to reimburse Sanofi Pasteur, at the dollar value, the Source Plasma in case of damage or loss.\",\n          \"text\": \"The Compensation Fee\\\" is defined as the dollar value.\"\n        }\n      ]\n    },\n    {\n      \"summary\": \"ADMA declares the Compensation Fee is fair and equitable.\",\n      \"text\": \"The source plasma shall, as between Sanofi Pasteur and ADMA, transfer to ADMA\"\n    },\n    {\n      \"summary\": \"Each Party releases, remises and forever discharges the other Party, and its Affiliates, from all claims arising directly out of, or related to the Updated Supply Plan and/or the amount of the Compensation Fee Sanofi agrees to pay to ADMA.\",\n    }\n  ]\n}\n```",
    "file_id": "ADMA BioManufacturing, LLC -  Amendment 3 to Manufacturing Agreement"
  },
  {
    "summary": "Consulting Agreement between Aduro Biotech, Inc. and IREYA B.V. regarding services, compensation, term, confidentiality, and intellectual property.",
    "contract_type": "Affiliate Agreement",
    "parties": [
      {
        "name": "Aduro Biotech, Inc.",
        "location": "740 Heinz Avenue, Berkeley, CA 94710",
        "role": "Client"
      },
      {
        "name": "IREYA B.V.",
        "location": "Staalwijkstraat 16, 2313 XR Leiden, Netherlands",
        "role": "Consultant"
      }
    ],
    "effective_date": "2020-07-01",
    "contract_scope": "Service provision and ongoing consultation on research and development.",
    "duration": "December 31, 2020",
    "end_date": null,
    "total_amount": null,
    "governing_law": "California",
    "clauses": [
      {
        "summary": "Renewal & Termination",
        "clause_type": "Renewal & Termination"
      },
      {
        "summary": "Confidentiality & Non-Disclosure",
        "clause_type": "Confidentiality & Non-Disclosure"
      },
      {
        "summary": "Non-Compete & Exclusivity",
        "clause_type": "Non-Compete & Exclusivity"
      },
      {
        "summary": "Liability & Indemnification",
        "clause_type": "Liability & Indemnification"
      },
      {
        "summary": "Service-Level Agreements",
        "clause_type": "Service-Level Agreements"
      }
    ],
    "file_id": "ADUROBIOTECH,INC_06_02_2020-EX-10.7-CONSULTING AGREEMENT(1)"
  },
  {
    "summary": "Consulting Agreement between Aduro Biotech, Inc. and IREYA B.V. regarding services provided, compensation, term, confidentiality, and intellectual property.",
    "contract_type": "Consulting Agreement",
    "parties": [
      {
        "name": "Aduro Biotech, Inc.",
        "location": "740 Heinz Avenue, Berkeley, CA 94710"
      },
      {
        "name": "IREYA B.V.",
        "location": "Staalwijkstraat 16, 2313 XR Leiden, Netherlands"
      },
      {
        "name": "Stephen T. Isaacs",
        "title": "President and Chief Executive Officer"
      },
      {
        "name": "Andrea van Elsas",
        "title": "Chief Scientific Officer"
      }
    ],
    "effective_date": "2020-07-01",
    "contract_scope": "Services provided to provide advice and consultation regarding research and clinical development programs.",
    "duration": "Until December 31, 2020 (unless extended or earlier terminated)",
    "end_date": "2020-12-31",
    "total_amount": "null",
    "governing_law": "California",
    "clauses": [
      {
        "summary": "Renewal & Termination",
        "clause_type": "Renewal & Termination"
      },
      {
        "summary": "Confidential Information",
        "clause_type": "Confidential Information"
      },
      {
        "summary": "Non-Compete & Exclusivity",
        "clause_type": "Non-Compete & Exclusivity"
      },
      {
        "summary": "Liability & Indemnification",
        "clause_type": "Liability & Indemnification"
      },
      {
        "summary": "Service-Level Agreements",
        "clause_type": "Service-Level Agreements"
      }
    ],
    "file_id": "ADUROBIOTECH,INC_06_02_2020-EX-10.7-CONSULTING AGREEMENT"
  },
  {
    "acceptance": [
      {
        "date": "2023-10-27",
        "signature": "John M. Lisicki"
      },
      {
        "date": "2023-10-27",
        "signature": "John M. Lisicki"
      },
      {
        "date": "2023-10-27",
        "signature": "John M. Lisicki"
      }
    ],
    "file_id": "AFSALABANCORPINC_08_01_1996-EX-1.1-AGENCY AGREEMENT"
  },
  {
    "agreement": [
      "Schedule A",
      "Schedule C",
      "Schedule A",
      "Schedule C",
      "Schedule A",
      "Schedule C",
      "Schedule A",
      "Schedule C",
      "Schedule A",
      "Schedule C",
      "Schedule A",
      "Schedule C",
      "Schedule A",
      "Schedule C",
      "Schedule A",
      "Schedule C",
      "Schedule A",
      "Schedule C",
      "Schedule A",
      "Schedule C",
      "Schedule A",
      "Schedule C",
      "Schedule A"
    ],
    "file_id": "AgapeAtpCorp_20191202_10-KA_EX-10.1_11911128_EX-10.1_Supply Agreement"
  },
  {
    "contact_information": {
      "Charles Liles": "626-737-8118",
      "Jason I. Spark Canale": "619-849-6005",
      "Canale Comm": "646-564-2156",
      "Email": "contact@xencor.com"
    },
    "company_information": {
      "company_name": "Xencor, Inc.",
      "industry": "Biopharmaceutical",
      "legal_status": "Inc.",
      "registered_trademarks": [
        "XmAb",
        "Xencor",
        "AIMMUNE",
        "AIMMUNETheraetics"
      ]
    },
    "press_release_information": {
      "content": "Xencor, Inc. has granted an exclusive worldwide license to develop and commercialize the investigational humanized monoclonal antibody XmAb7195 to Aimmune Therapeutics, Inc.  XmAb7195, which has been renamed AIMab7195, was originally developed by Xencor for the treatment of allergic asthma.  Aimmune Therapeutics will make an upfront payment to Xencor of $5 million in cash and $5 million in equity, equivalent to 156,238 newly issued shares of Aimmune common stock at $32.0025/share."
    },
    "file_id": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement"
  }
]